GIP and metabolic disease: For research purposes, multiple GIP analogs that resist DPP-4 degradation have been synthesized, including N-AcGIP (Mabilleau et al., 2014), Pro3GIP (Yang et al., 2022), and D-Ala2-GIP (Killion et al., 2020) to study various metabolic diseases.